Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016861 · ClinicalTrials.gov registry record · Phase 1
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
A Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by Texas Children's Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00016861 is a Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific that has completed, run by Texas Children's Cancer Center. The trial reports 1 study location across 1 state.
The verdict
NCT00016861, a Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific, has completed, sponsored by Texas Children's Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children who have refractory or progressive solid tumors.
Conditions Studied
Interventions
- DRUG irinotecan hydrochloride
Study Locations (1)
Texas
- Texas Children's Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Est. Completion | 2005-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016861
The ClinicalTrials.gov registry entry for NCT00016861 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Texas Children's Cancer Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Childhood Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which irinotecan hydrochloride is the first listed.
NCT00016861 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00016861 about?
NCT00016861 is a clinical study titled "Irinotecan in Treating Children With Refractory or Progressive Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children who have refractory or progressive solid tumors.
What is the current status of trial NCT00016861?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-09. Estimated completion is 2005-01.
What conditions does trial NCT00016861 study?
This clinical trial studies the following conditions: Unspecified Childhood Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00016861?
The interventions under investigation include: irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00016861?
This trial is sponsored by Texas Children's Cancer Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00016861 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Childhood Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
COMPLETED · Phase 1
-
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
COMPLETED · Phase 1
-
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
COMPLETED · Phase 1
-
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
COMPLETED · Phase 1
-
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.